|
Subgroup analyses
|
No. of studies
|
No. of patients
|
Sensitivity (95%CI)
|
Specificity (95%CI)
|
AUC (95%CI)
|
PLR (95%CI)
|
NLR (95%CI)
|
DOR (95%CI)
|
|---|
|
Laboratory-based immunoassay
|
|
Overall studies
|
11
|
1110
|
0.96 (0.90–0.98)
|
0.97 (0.95–0.99)
|
0.99 (0.98–1.00)
|
35.0 (18.5–66.2)
|
0.04 (0.02–0.11)
|
811 (220–2990)
|
|
Excluded metallosis
|
|
Yes
|
4
|
416
|
0.97 (0.88–0.99)
|
0.99 (0.96–1.00)
|
0.99 (0.98–1.00)
|
80.7 (26.0–251.1)
|
0.03 (0.01–0.13)
|
2447 (383–15,647)
|
|
No and NA
|
7
|
694
|
0.94 (0.84–0.98)
|
0.96 (0.94–0.97)
|
0.98 (0.96–0.99)
|
23.1 (14.2–37.6)
|
0.06 (0.02–0.17)
|
382 (103–1414)
|
|
Study design
|
|
Prospective
|
6
|
697
|
0.97 (0.92–0.99)
|
0.98 (0.96–0.99)
|
0.99 (0.98–1.00)
|
42.9 (22.9–80.4)
|
0.03 (0.01–0.09)
|
1480 (423–5172)
|
|
Retrospective
|
5
|
413
|
0.91 (0.79–0.96)
|
0.95 (0.90–0.98)
|
0.98 (0.96–0.99)
|
19.9 (8.9–44.5)
|
0.10 (0.04–0.24)
|
207 (52–830)
|
|
Lateral flow test
|
|
Overall studies
|
10
|
933
|
0.86 (0.81–0.91)
|
0.96 (0.93–0.98)
|
0.95 (0.93–0.97)
|
21.2 (11.7–38.5)
|
0.14 (0.10–0.21)
|
148 (64–343)
|
|
Excluded antibiotic therapy
|
|
Yes
|
5
|
462
|
0.86 (0.77–0.92)
|
0.97 (0.91–0.99)
|
0.94 (0.92–0.96)
|
32.7 (9.3–114.6)
|
0.15 (0.08–0.25)
|
225 (46–1099)
|
|
No and NA
|
5
|
471
|
0.87 (0.78–0.92)
|
0.95 (0.91–0.97)
|
0.97 (0.95–0.98)
|
17.3 (9.1–33.1)
|
0.14 (0.08–0.23)
|
124 (46–336)
|
|
Number of patients
|
|
≥ 50
|
7
|
826
|
0.89 (0.84–0.92)
|
0.97 (0.94–0.99)
|
0.95 (0.92–0.96)
|
30.9 (15.4–61.9)
|
0.12 (0.08–0.17)
|
263 (109–631)
|
- PLR positive likelihood ratio, NLR negative likelihood ratio, DOR diagnostic odds ratio, AUC area under the curve
